Azurrx Biopharma Inc (AZRX) Stock Price, Forecast & Analysis
USA - NASDAQ:AZRX -
AZRX Key Statistics, Chart & Performance
The current stock price of AZRX is 3.45 null. In the past month the price decreased by -40.65%. In the past year, price decreased by -52.21%.
AZRX Latest News, Press Relases and Analysis
AZRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About AZRX
Company Profile
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Delray Beach, Florida and currently employs 12 full-time employees. The company went IPO on 2016-10-11. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company focused on developing its pipeline of gut-restricted GI clinical drug candidates, including MS1819 and niclosamide. Its therapeutic product pipeline consists of three clinical-stage programs. The Company’s lead drug candidate is MS1819. The company is a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). The company is an an oral non-systemic biologic capsule. MS1819 is in two Phase II CF clinical trials. The company is a pro-inflammatory pathway inhibitor, is a prescription small molecule drug that has been safely used on millions of patients.
Company Info
Azurrx Biopharma Inc
1615 SOUTH CONGRESS AVENUE, SUITE 103
Delray Beach FLORIDA 33445 US
CEO: James Sapirstein
Employees: 12
Phone: 16466997855.0
Azurrx Biopharma Inc / AZRX FAQ
What does AZRX do?
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Delray Beach, Florida and currently employs 12 full-time employees. The company went IPO on 2016-10-11. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company focused on developing its pipeline of gut-restricted GI clinical drug candidates, including MS1819 and niclosamide. Its therapeutic product pipeline consists of three clinical-stage programs. The Company’s lead drug candidate is MS1819. The company is a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). The company is an an oral non-systemic biologic capsule. MS1819 is in two Phase II CF clinical trials. The company is a pro-inflammatory pathway inhibitor, is a prescription small molecule drug that has been safely used on millions of patients.
What is the stock price of Azurrx Biopharma Inc today?
The current stock price of AZRX is 3.45 null. The price increased by 2.07% in the last trading session.
Does Azurrx Biopharma Inc pay dividends?
AZRX does not pay a dividend.
What is the ChartMill rating of Azurrx Biopharma Inc stock?
AZRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does Azurrx Biopharma Inc belong to?
Azurrx Biopharma Inc (AZRX) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of Azurrx Biopharma Inc (AZRX)?
Azurrx Biopharma Inc (AZRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.78).
AZRX Technical Analysis
AZRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AZRX. AZRX has a bad profitability rating. Also its financial health evaluation is rather negative.
AZRX Financial Highlights
Over the last trailing twelve months AZRX reported a non-GAAP Earnings per Share(EPS) of -0.78. The EPS decreased by -32.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -288.01% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
AZRX Forecast & Estimates
4 analysts have analysed AZRX and the average price target is 3.4 null. This implies a price decrease of -1.45% is expected in the next year compared to the current price of 3.45.